"Bloomberg" today reports that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is likely to name board member Erez Vigodman as CEO this month, citing two sources. Vigodman will succeed Dr. Jeremy Levin, who was ousted in October 2013 over confrontations and friction with Teva's board of directors.
"Bloomberg" says, "Vigodman, the CEO of generic agrochemicals maker Makhteshim Agan Industries Ltd., is the board’s choice for the job, though directors haven’t voted on the appointment yet, said the people, who asked not to be identified because the search is confidential."
"As critical as I am of Teva’s board, I think this time they got it right,” wrote Benny Landa, a director in Teva in a letter to shareholders yesterday that was obtained by "Bloomberg News". “Erez Vigodman is made of the right stuff to succeed. He is a strategic thinker with excellent managerial skills. He is a straight shooter whom the Street will learn to trust."
Published by Globes [online], Israel business news - www.globes-online.com - on January 6, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014